Amphastar Sees Its Strongest Quarter So Far

As Company Continues To Develop Seven Generics

Amphastar has delivered a strong quarter due to an increased in sales of higher-margin products. The company continues to target a combined market worth around $10.5bn with seven generics in development. 

Amphastar continues to develop its pipeline and diversify its portfolio • Source: Alamy

Amphastar Pharmaceuticals has reported one of its “strongest quarters” with net revenues of $103m for the first quarter ending 31 March 2021, compared to $84m reported in prior-year period. The company has attributed the revenue growth to increase in sales of higher margin products such as Primatene Mist (epinephrine), glucagon and epinephrine injection multi-dose vials.

Jack Zhang, president and CEO of Amphastar, commented that “the launch of glucagon, along with strong sales growth of Primatene...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business